<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/24/taiwan-liposome-s-nasdaqtlc-receives-consensus-rating-of-buy-from-brokerages.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-24T19:28:41+00:00"/>
    <meta property="og:title" content="TAIWAN LIPOSOME/S (NASDAQ:TLC) Receives Consensus Rating of “Buy” from Brokerages"/>
    <meta property="og:description" content="Shares of TAIWAN LIPOSOME/S (NASDAQ:TLC) have earned an average rating of “Buy” from the six brokerages that are presently covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have issued a report on the stock in the last year […]"/>
  </head>
  <body>
    <article>
      <h1>TAIWAN LIPOSOME/S (NASDAQ:TLC) Receives Consensus Rating of “Buy” from Brokerages</h1>
      <address><time datetime="2019-11-24T19:28:41+00:00">24 Nov 2019, 19:28</time> by <a rel="author" href="https://www.thecerbatgem.com/author/jessica" target="_blank">Jessica Moore</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/generic-stocks.jpg"/>
      </figure>
      <p>Shares of TAIWAN LIPOSOME/S (NASDAQ:TLC) have earned an average rating of “Buy” from the six brokerages that are presently covering the company, <a href="https://www.marketbeat.com/">Marketbeat.com</a> reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have issued a report on the stock in the last year is $8.92.</p>
      <p>Several equities research analysts have recently weighed in on TLC shares. Cantor Fitzgerald reissued an “overweight” rating on shares of TAIWAN LIPOSOME/S in a report on Friday, October 18th. <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> raised TAIWAN LIPOSOME/S from a “hold” rating to a “buy” rating and set a $5.75 price objective for the company in a report on Saturday, October 26th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of TAIWAN LIPOSOME/S in a report on Wednesday, October 23rd.</p>
      <p><a href="https://www.marketbeat.com/stocks/NASDAQ/TLC/price-target/">TLC</a> traded up $0.08 on Friday, hitting $5.08. The company had a trading volume of 2,000 shares, compared to its average volume of 1,017. The company’s fifty day moving average price is $5.06 and its 200 day moving average price is $5.25. The company has a current ratio of 2.69, a quick ratio of 2.69 and a debt-to-equity ratio of 0.73. The firm has a market cap of $162.66 million and a P/E ratio of -10.81. TAIWAN LIPOSOME/S has a 1 year low of $4.61 and a 1 year high of $11.00.</p>
      <p>
        <b>TAIWAN LIPOSOME/S Company Profile</b>
      </p>
      <p>Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site.</p>
      <p>Featured Article: <a href="https://www.marketbeat.com/financial-terms/understanding-market-liquidity/">Understanding Market Liquidity</a></p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=TLC"/>
      </figure>
    </article>
  </body>
</html>